Filing Flows

Filing Flows › 8-K events › Neuronetics

Neuronetics: results of operations

Form 8-K filed Nov 4, 2026 · items 2.02, 7.01

FDA decisionsNeuronetics Reports Third Quarter 2026 Financial and Operating Results

What the filing says

Neuronetics Reports Third Quarter 2026 Financial and Operating Results MALVERN, PA., November 4, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar ® TMS technology and direct patient care through the Greenbrook network of interve

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Neuronetics at a glance

Latest quarterQ3 2026
Revenue$42.0M
Revenue Y/Y+12%
Operating margin1.3%
IndustrySurgical & Medical Instruments & Apparatus

Neuronetics, Q3 2026: revenue $42.0M (+12% year over year), operating margin 1.3%. The chart follows the revenue to costs, profit and cash.

Neuronetics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.